CME 9 Session - EANM'16

Drug Development/Radiopharmacy/Translational Molecular Imaging: Strength and Limitations of Techniques and Instrumentation

Educational objectives:
  1. Understand how the cyclotrons are advancing their capacity to serve the medical field with new machines, new technology, and new uses
  2. How LC-MS/MS can speed up and make tracer development more efficient
  3. The development of these technologies for use in drug discovery and nuclear medicine
  4. Benefits and limitations of multimodality approach

Molecular imaging is a powerful approach for the early diagnosis and determination of treatment efficacy. For the field to progress it requires more efficient and productive approaches to generate the appropriate tools (e.g. radiopharmaceuticals, multimodal imaging approaches) to be able to perform stratified or personalized medicine in order to meet the current demand. This is being achieved by the continual evolution in methods for radiopharmaceutical development. Two concepts have been championed: ‘satellite radiotracer distribution’, and the “dose on demand” concepts. What is the future for these competing concepts? Recent developments in preclinical and clinical imaging has seen a drive towards multi-modality PET-MR imaging. Does this improve diagnosis, is it a chimera or will it find a ‘killer’ application and become the standard in molecular imaging of the future? Are multimodal imaging agents a pipe dream?

Key Words:

Cyclotrons, babycyclotron, LC-MS/MS, radiometabolites, PET-MRI, multimodal imaging

User action required
If you have the permission to view this publication, please log in.